Anzeige
Mehr »
Login
Samstag, 27.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Geheimtipp: Rasanter Aufstieg, Branchenrevolution und Jahresumsatz von 50 Mio. $
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
476 Leser
Artikel bewerten:
(2)

Lumenis Announces NuEra Tight with FocalRF Technology, a Breakthrough in Aesthetic Medical Devices, now available in Europe and the Middle East offering Personalized Body Sculpting Treatments

YOKNEAM, Israel, Sept. 7, 2020 /PRNewswire/ -- Lumenis Ltd., the world's largest energy-based medical device company for aesthetic, surgical and ophthalmic applications, is proud to announce the revolutionary NuEra Tight with FocalRF technology, now available in Europe and the Middle East. Body Sculpting takes on a whole new meaning with NuEra Tight offering a personalized solution for Fat Reduction, Skin Tightening, Cellulite and Wrinkle Reduction, all in one device.

Lumenis_Logo

NuEra Tight with FocalRF technology was developed to provide tailored body sculpting treatments to a patient's distinctive needs. The new technology gives treatment providers advanced tools for today's aesthetic patients, accounting for clinical indications and specific body areas.

"One size doesn't fit all. That's why we revolutionized the NuEra Tight," said Tzipi Ozer-Armon, CEO of Lumenis. "We recognized the need for the next level solution in non-invasive body sculpting treatments, which led us to develop this advanced product. NuEra Tight with FocalRF technology tailors treatments to a clinical indication and body area, accurately targeting various skin and tissue conditions throughout the procedure, resulting in a treatment that is as unique as your patients."

"More and more of my patients are looking to eliminate fat in stubborn areas and tighten their skin to sculpt their body and address skin texture issues such as cellulite and wrinkles," said Freeda Tannous M.D., Dermatologist, Amman, Jordan. "Thanks to FocalRF technology I am now able to tailor the treatment specifically for each patient needs achieving the desired improved appearance."

The system's easy to use interface features NuAPIC (Automatic Personalized Intelligent Control) which ensures the therapeutic temperature throughout the procedure, as well as the innovative NuLogic advanced protocol customization tool, that enhances further personalization for optimal treatment.

"Offering my patients nonsurgical body contouring targeting multi-indications in one session with one device is an incredible advantage," said Giovanni Luigi Rizzi, M.D., Milan, Italy. "NuEra Tight can be applied for the entire range of body sculpting treatments, it is the only body device a clinic needs."

NuEra Tight is available in the US, APAC, Europe and the Middle East in accordance to local regulatory requirements and will be launched in additional countries later this year.

Please visit lumenis.com for more information about the Lumenis family of products.

About Lumenis

Lumenis is a global leader in the field of minimally-invasive clinical solutions for the Surgical, Ophthalmology, and Aesthetic markets, and is a world-renowned expert in developing and commercializing innovative energy-based technologies, including Laser, Intense Pulsed Light (IPL) and Radio-Frequency (RF). For over 50 years, Lumenis' ground-breaking products have redefined medical treatments and have set numerous technological and clinical gold-standards. Lumenis has successfully created solutions for previously untreatable conditions, as well as designed advanced technologies that have revolutionized existing treatment methods. Lumenis is a portfolio company of Baring Private Equity Asia.

For further information, contact 5W Public Relations at Lumenis@5wpr.com.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2020 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.